Is Ionis Pharmaceuticals, Inc. (IONS) a Buy, Sell, or Hold?
NASDAQ : IONS
Ionis Pharmaceuticals, Inc.
$56.55 USD
$0.68 (1.22%)
- Volume
- 3.09M
- Average Volume
- 2.7M
- Market Capitalization
- $9.35B
- P/E Ratio
- -28.42
- Dividend Yield
- 0.00%
- Price Target
- $89.50
- Year High
- $86.74
- Year Low
- $40.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.10
Company Overview
NASDAQ
Brett Monia
Biotechnology
Healthcare
IONS
1402
US
USD
Liquidity Metrics
4.15
4.10
4.09
0.24
0.00
Sales & Valuation
$944M
8.83
18.97
-9.62
-5.89
Profitability
-$2.38
-$381M
-30.87%
-30.74%
-58.57%
-9.47%
P/E Metrics
-28.42
5.30
5.30
Analyst Price Target & Rating
$89.50
$130.00
$75.00
1/5
33 Analysts
-36.82%
Financial Health Scores
1.63
2/9
$2.22B
$3.45B
$2.96B
-$248.37M
Key Metrics (TTM)
$11.21B
10.60
2.45
4.10
-58.57%
-11.14%
-3.50%
-10.39%
-402 days
Company Executives
| Name | Title |
|---|---|
| Darren Gonzales | Chief Accounting Officer & Senior Vice President |
| D. Wade Walke | Senior Vice President of Investor Relations |
| Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary |
| Brian Birchler | Executive Vice President of Corporate & Development Operations |
| C. Frank Bennett | Executive Vice President & Chief Scientific Officer |
| Elizabeth L. Hougen | Executive Vice President of Finance & Chief Financial Officer |
| Eric E. Swayze | Executive Vice President of Research |
| Eugene Schneider | Executive Vice President, Chief Clinical Development & Operations Officer |
| Brett Monia | Founder, Chief Executive Officer & Director |
| Richard S. Geary | Strategic Consultant |
Poll Results
No votes yet today — be the first to share your view!
About Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all fo ... rms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
2026-07-23 11:30:00
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
2026-07-23 10:00:00
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-21 13:27:00
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-21 03:17:21
Amova Asset Management Americas Inc. reduced its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 12.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 81,696 shares of the company's stock after selling 11,875 shares during the quarter. Amova
Ionis Pharmaceuticals: The Heartbreak Is Priced In
2026-07-16 18:09:36
The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis's wholly owned core assets. Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market. Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven.
2026-07-16 10:00:00
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-15 16:02:00
SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
2026-07-15 11:55:43
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
Frequently Asked Questions
-
What is the current Ionis Pharmaceuticals, Inc. (IONS) stock price?
-
Ionis Pharmaceuticals, Inc.(NASDAQ:IONS) stock price is $56.55 in the last trading session. During the trading session, IONS stock reached the peak price of $86.74 while $40.03 was the lowest point it dropped to. The percentage change in IONS stock occurred in the recent session was 1.22% while the dollar amount for the price change in IONS stock was $0.68.
-
IONS's industry and sector of operation?
-
The NASDAQ listed IONS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IONS?
-
Darren Gonzales | Chief Accounting Officer & Senior Vice President
D. Wade Walke | Senior Vice President of Investor Relations
Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary
Brian Birchler | Executive Vice President of Corporate & Development Operations
C. Frank Bennett | Executive Vice President & Chief Scientific Officer -
How many employees does IONS have?
-
Number of IONS employees currently stands at 1402. IONS operates from 2855 Gazelle Court, Carlsbad, CA 92010, US.
-
Link for IONS official website?
-
Official Website of IONS is: https://www.ionis.com
-
How do I contact IONS?
-
IONS could be contacted at phone #760 931 9200 and can also be accessed through its website. IONS operates from 2855 Gazelle Court, Carlsbad, CA 92010, US.
-
How many shares of IONS are traded daily?
-
The average number of IONS shares traded daily for last 3 months was 2.7M.
-
What is the market cap of IONS currently?
-
The market value of IONS currently stands at $9.35B with its latest stock price at $56.55